A CT-14 license is essential for manufacturers aiming to create formulations using unapproved Active Pharmaceutical Ingredients (APIs) exclusively for Clinical Trials (CT), analysis, or Bioavailability/Bioequivalence (BA/BE) studies. Here's the process for both integrated and separated API and formulation manufacturers:
For Integrated API and Formulation Manufacturers:
For Separated API and Formulation Manufacturers:
A manufacturer holding either a Manufacturing License in Form-25/28/29 issued by SLA, a copy of Form 37 issued by SLA, DSIR approval for formulations, or a copy of approval for a BA/BE centre is eligible to apply for the license
The Applicant must follow the following process:
![]() |
Access the Sugam Portal and log in to your account. |
![]() |
Navigate to the "Submit new application" section. · |
![]() |
Select "Test License" and then proceed to choose "Form CT-12." · |
![]() |
Provide the pharmaceutical information for the drug, specify the details of the sites involved in the study, and complete all other relevant sections as indicated. |
![]() |
Attach all the necessary documents as outlined in CT-12. · |
![]() |
Make the required government fee payment. · |
![]() |
Then click on “Submit” and apply. · |
![]() |
Keep track of any potential inquiries or requests for clarification from the CDSCO and subsequently obtain approval in the form of CT-14. |
The time frame for obtaining the license is approximately 90 days and the duration of validity is three years from the date of issuance unless the authority suspends or cancels it.
The essential documents needed to acquire licenses are as follows:
Form 29from Central Drugs Standard Control Organisation
90
DAYSPlease provide valid & attested Administrative documents as per the checklist.
You should submit this application to the relevant Zonal/ Sub-zonal offices of CDSCO.
You need to submit this application to the CDSCO Headquarters, which is located at FDA Bhavan in New Delhi. This should be done in conjunction with your application for permission to carry out the CT or BA/BE study, depending on your specific circumstances.
If a new drug, manufactured for the purpose of CT or BA/BE studies, or for examination, testing, and analysis, is damaged, left unused, or is determined to be of substandard quality, or has surpassed its specified shelf life, it must be disposed of, and the corresponding actions should be documented.